Immuno-oncology
Expert Solutions. Driving Clinical Trial Advancements.
Supporting precision immuno-oncology through tailored immunological insights.
Nexomics serves as the crucial nexus between the world-renowned diagnostic pathology expertise of Peter MacCallum Cancer Centre and the evolving demands of immunology oncology clinical trials.
We offer established flow cytometry diagnostic panels and development and validation of custom-designed traditional and spectral cytometry panels; all meticulously tailored to your specific needs within designated cancer types and international diagnostic guidelines.
This personalised approach facilitates precise measurement of therapeutic efficacy, enabling you to accelerate your drug development pipeline with confidence.
Cellular responses as observed by soluble factor production
Developing & Validating Immunology Assays
As immunology specialists, we push the field forward through the development and validation of new immune monitoring assays to support clinical investigations of immune system disorders. Our in-depth expertise in flow cytometry led to the generation of guidelines and protocols tailored to immunological studies, including intra-cellular assay guidelines.
Benefits of using multiplex ELISA technology:
- Cost-effective: Efficiently quantifies multiple analytes from a single sample, reducing reagent and labour costs compared to multiple single-plex assays.
- High-throughput capabilities: Multiplex capabilities of up to 50 analytes per run, significantly accelerating data acquisition.
- Quantitative with high sensitivity: Delivering precise quantitative results with sensitivity down to the picogram (pg/mL) or femtogram (fg/mL) range, depending on the analyte and assay.
- Extensive experience: Broad experience in utilizing and developing assays with commercially available kits and custom solutions.
- Minimised sample volume: Broad application with small sample volumes required (typically 25-50 µL or less), preserving precious clinical samples.
- Versatile sample input: Broad applicability across diverse biological matrices, including plasma, serum, cell culture supernatant, cerebrospinal fluid (CSF), urine, and tissue lysates.
COMPREHENSIVE multi-parametric panels
Precise Identification. Deeper Cell Insight.
With our state-of-the-art instrumentation and expert scientific team, we will provide you with a wealth of information, from a broad overview of many populations to a detailed picture of your specific cells of interest. Our expertise in the design of complex multi-parametric panels will allow you to look at all your markers of interest in a single assay, thereby optimise the use of your samples.
The wide range of applications of our platform includes:
- Phenotyping of all major cell lineages (TBNK, Treg, MDSC, etc.) and rare cell subsets (basophils, stem cells, antigen-specific cells, etc.).
- Monitoring cell subsets or biomarkers with various flow panels including intracellular cytokine staining and functional assays.
specialised and bespoke flow cytometry testing
Cellular Phenotyping by Flow Cytometry
Our scientists are flow cytometry specialists who understand your project’s objectives and what it takes to meet them. From beginning to end, our service will provide you with:
- Expertise in developing assays for the identification and characterisation of major and minor cell lineages.
- Assay customisation to obtain comprehensive data best adapted to your study goals.
- Reliable analysis delivered to meet your clinical trial requirements.
- Rigorous quality control in accordance with the relevant regulatory requirements (GCP, GLP, GCLP) and ISAC data standards.
COMPREHENSIVE oncology panels
Specialised Diagnostic Immunology
In addition to comprehensive baseline immunophenotypic characterisation of haematological malignancy, our flow cytometry laboratory also offers novel flow cytometric approaches including
- Measurable residual disease (MRD) testing in lymphoblastic leukaemia, acute myeloid leukaemia, chronic lymphocytic leukaemia and myeloma.
- Immunophenotypic characterisation of T-cell clonality by TRBC expression.
- Immunophenotypic quantification and characterisation of CART expressing T-cells post CART therapy.
“As leaders in Pathology, we strive for excellence. We advocate for our patients through exceptional service, innovative research and personalised clinical care.”
The Department of Pathology, Peter MacCallum Cancer Centre
